Slide

Pharnext Announces a New Financing Through a Convertible Bond Program for a Total Amount up to €81 Million Gross to Extend its Cash Runway and to Continue to Fund its Pivotal Phase III Study of PXT3003, the PREMIER trial, in Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)

Pharnext SA, an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY™ platform, today announced the entry into a convertible bonds financing agreement with Global Tech Opportunities 13, in which Alpha Blue Ocean acted as arranger, by means of the issuance of 8,100 warrants giving access to bonds convertible into new shares or exchangeable for existing shares with a par value of €10,000 each in several tranches.